A monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants

SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibodies (mAbs) were derived from ancestral or early Omicron strains and have lost activity against recent variants, limiting their ability to resolve the antigenic effects of mutations arising in emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune mice with the KP.3.1.1 spike, and isolated and characterized 11 human neutralizing antibodies targeting diverse epitopes of evolved variants. We then integrated these antibodies with characterized mAbs to establish a toolbox for profiling antigenic evolution among emerging variants. Application of this panel to emerging variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.

Authors

Institutions

Publication Details

Journal
Cell Reports
Published
2026-11-19
DOI
https://doi.org/10.1016/j.celrep.2026.118355
Citations
2
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
6.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants

Jian Yu, Yicheng Guo, David D. Ho, Ian A. Mellis et al.
2 citations
Cell Reports
SARS-CoV-2 and COVID-19 Research
6.04
article

A monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants

Jian Yu, Yicheng Guo, David D. Ho, Ian A. Mellis, Yaoxing Huang, Hsiang Hong, Madeline Wu, Sue Chong, Qian Wang, Chien-Yu Huang
article en
2 citations

Abstract

SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibodies (mAbs) were derived from ancestral or early Omicron strains and have lost activity against recent variants, limiting their ability to resolve the antigenic effects of mutations arising in emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune mice with the KP.3.1.1 spike, and isolated and characterized 11 human neutralizing antibodies targeting diverse epitopes of evolved variants. We then integrated these antibodies with characterized mAbs to establish a toolbox for profiling antigenic evolution among emerging variants. Application of this panel to emerging variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.

Cell ReportsVol. 45(12)
Aaron Diamond AIDS Research Center (US), National Taiwan University (TW), Columbia University (US)
Bill and Melinda Gates Foundation, National Institutes of Health
Good health and well-being
Openalex Percentile: Top 6%
SARS-CoV-2 and COVID-19 Research
6.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon